| Name | Title | Contact Details |
|---|
Fresenius Kabi is a global health care company that specializes in lifesaving medicines and medical technologies for infusion, transfusion and clinical nutrition. Our expansive portfolio of products and global network of science and manufacturing centers provide essential support for the care of critical and chronically ill patients. We are part of Fresenius SE, a health care group with more than 100 years of experience in pharmaceuticals, medical devices and life sciences. Our employees – more than 35,000 worldwide – develop and deliver injectable pharmaceuticals and infusion systems; blood collection, transfusion and cell technologies; and essential nutrients for parenteral nutrition. We have special expertise in medicines for oncology, infection, anesthesia, analgesia and critical care. Our products are used in all sites of care – from hospitals and clinics to blood and plasma centers, and increasingly in patients’ homes. In biosimilars, we are developing products with a focus on oncology and autoimmune diseases.
Chem Rx Corporation, formerly Paramount Acquisition Corp., provides institutional pharmacy services to skilled nursing facilities, assisted living facilities, residential living facilities, addiction treatment centers and other long-term healthcare
Tampa, Florida - NeuX Technologies is a health, wellness, fitness and human performance company developing proprietary products and solutions for chronic pain, musculoskeletal injuries, neuromuscular conditions/diseases, fitness and human performance.
WIL Research Company, Inc. is a privately held global Contract Research Organization that provides product safety toxicological research, bioanalytical, and formulation services to the pharmaceutical, biotechnology, chemical, agrochemical, and food products industries as well as manufacturing support for clinical trials.
Enochian BioSciences (formerly DanDrit Biotech USA Inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for HIV/AIDS and cancer.